Danaparoid Sodium

Drug #1688

Danaparoid Sodium is a heparinoid representing a mixture of low-molecular weight sulfated glycosaminoglycans: heparan (not heparin) sulfate (84%), dermatan sulfate (12%), and chondroitin sulfate (4%). Danaparoid is obtained from porcine intestinal mucosa after the removal of heparin. The mean molecular weight of danaparoid is 5500 daltons. Danaparoid Sodium is used for prophylaxis of deep-vein thrombosis in patients undergoing general or orthopaedic surgery, and in the management of thromboembolic disease in patients with history of heparin-induced thrombocytopenia.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 5500 · Non-proprietary name: Danaparoid Sodium.

Molecular structure of Danaparoid Sodium

Pharmacokinetics

Absorption: Danaparoid Sodium has an oral bioavailability is 100%.

Elimination: plasma half-life is 24 hours.

Indications

Danaparoid Sodium is primarily indicated in conditions like Endometrial thinning before intra-uterine surgery, Prophylaxis of venous thromboembolism.

Contraindications

Danaparoid Sodium is contraindicated in conditions like Peptic ulcer, Traumatic injury, Acute musculoskeletal disorders, Relief of sore throat, Initial treatment of acute conditions, Pain management, General dose, Following coronary bypass surgery.

Dosage

Danaparoid Sodium's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0 – 0	—	—	IV	For patients with heparin-induced thrombocytopenia
750 Xa units	750 Xa units	Every 12h	SC	Dose should begin one to four hours prior to hip replacement surgery, and then no sooner than two hours after surgery. Treatment should be continued until the risk of deep venous thrombosis has diminished, usually within seven to ten days, but may be continued for up to fourteen days.
Paediatric Dosage (20kg)
400 unit/hr	400 unit/hr	—		Maintanace dose for 5 days.
1250 unit	1250 unit	—		Initial dose for less than 55 kg and 3750 units for greater than 90 kg.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Danaparoid Sodium is known to cause more or less tolerable side effects which are usually transient. These include Bruising or pain at injection site, Hemorrhage, Hypersensitivity reactions, Thrombocytopenia.

Warnings / Precautions

Hepatic and renal impairment (avoid for prophylaxis if severe); pregnancy and breast-feeding. Presence of sulphite in ampoules may (especially in patients with asthma) lead to hypersensitivity (with bronchospasm and shock)

Interference in Pathology

Danaparoid Sodium may interfere in the diagnosis of Serum test for Creatinine and Glucose .

Available Brands

None recorded.

Drug Classification

1.10.2 — Anticoagulants/Platelet deaggregators